Managed project aspects for two cross-functional teams – R&D and Commercial – as well as the organization’s portfolio. • Generated and updated a monthly portfolio report detailing milestones, risks, and mitigation strategies by communicating with leaders across two R&D programs and five research projects. • Collaborated with Program Director to manage an 18-member research team. Developed and maintained project schedules, facilitated research and strategy team meetings, and compiled and managed meeting documentation.• Coordinated Commercial product launch team by maintaining project schedule in Smartsheets, building automated dashboards, facilitating meetings and their documentation, and tracking key activities and issues across eight functions.

Played major role as project lead and team member in antibody therapeutic hit-to-lead and lead optimization programs. • Advanced methods for antibody binding and functional screening on two different primary cell types from various species and tested 100+ antibodies across four targets to support Ohana’s contraception program. • Developed, optimized, and validated flow cytometry, immune-cell killing, and bead-based assays to measure and characterize cellular heterogeneity and drive technical proof-of-concepts to support four projects spanning two programs.• Trained team members across several teams on these techniques as a reliable source of high-quality data and expertise.

Established robust methods for antibody staining and detection by flow cytometry, cell sorting, and immunofluorescence (IF) microscopy by testing multiple antibodies across 10+ targets. Expressed, purified, and tested scFvs by ELISA, IF microscopy, and flow cytometry.

Analyzed the biophysical modifications of a redox-exchanged CD4 variant by amide hydrogen-deuterium exchange mass spectrometry to measure induced changes in conformational dynamics. Coauthored publication.Expressed, purified, and characterized several broadly neutralizing HIV antibodies by ELISA and western blot.

Established library design criteria to improve clinical developability of antibodies. Coauthored 2 publications.Combined yeast surface display and noncanonical amino acids to establish a high-throughput, versatile new method that can be used to develop and characterize bioconjugates, leading to coauthor in publication.

Designed and implemented experiments independently to investigate mass spectrometry as an alternative method for assessing N-terminal residues of proteins.Evaluated enzymatic digestion methods using a liquid handler robotic system including performing gel-electrophoresis to assess digestion completeness.Performed literature reviews, N-terminal labeling experiments, LC/MS analysis, database searching, data analysis, and presented findings to the Biological Mass Spectrometry Group.

Established methods for the generation of yeast surface display libraries for antibody discovery.Developed mammalian cell-based assays for high-throughput screening and qualitative analysis of candidate antibodies